Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in Acrivon Therapeutics, Inc.'s (NASDAQ:ACRV) instance, it's good news for shareholders.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
The Last 12 Months Of Insider Transactions At Acrivon Therapeutics
The Co-Founder Peter Blume-Jensen made the biggest insider purchase in the last 12 months. That single transaction was for US$82k worth of shares at a price of US$1.68 each. That means that an insider was happy to buy shares at around the current price of US$1.83. That means they have been optimistic about the company in the past, though they may have changed their mind. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. The good news for Acrivon Therapeutics share holders is that insiders were buying at near the current price. We note that Peter Blume-Jensen was both the biggest buyer and the biggest seller.
Over the last year, we can see that insiders have bought 67.83k shares worth US$114k. But they sold 18.75k shares for US$40k. In the last twelve months there was more buying than selling by Acrivon Therapeutics insiders. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
View our latest analysis for Acrivon Therapeutics
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
Insiders At Acrivon Therapeutics Have Sold Stock Recently
The last three months saw some Acrivon Therapeutics insider selling. Insiders only netted US$40k selling shares, in that period. It's not great to see insider selling, nor the lack of recent buyers. But the volume sold is so low that it really doesn't bother us.
Insider Ownership Of Acrivon Therapeutics
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 6.3% of Acrivon Therapeutics shares, worth about US$5.3m, according to our data. We do generally prefer see higher levels of insider ownership.
What Might The Insider Transactions At Acrivon Therapeutics Tell Us?
We did not see any insider buying in the last three months, but we did see selling. But given the selling was modest, we're not worried. But insiders have shown more of an appetite for the stock, over the last year. The transactions are fine but it'd be more encouraging if Acrivon Therapeutics insiders bought more shares in the company. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we've found that Acrivon Therapeutics has 4 warning signs (2 make us uncomfortable!) that deserve your attention before going any further with your analysis.
Of course Acrivon Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.